Sun Pharma gets US FDA approval for ILUMYA in psoriatic arthritis

Sun Pharmaceutical Industries announced it received US FDA approval for ILUMYA (tildrakizumab-asmn) for the treatment of psoriatic arthritis, a significant addition to its specialty portfolio in the US.

Detected & updated continuously · Source: Nebula